![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-desktop-header-1gif-4289.gif)
![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-mobgif-81230.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Under the terms of the agreement, Supernus and Navitor will jointly conduct a Phase II clinical program for NV-5138 in treatment-resistant depression (TRD).
Lead Product(s): NV-5138
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Supernus Pharmaceuticals
Deal Size: $475.0 million Upfront Cash: $25.0 million
Deal Type: Collaboration April 21, 2020